glp-1 news today october 23 2025 Mapping the effectiveness and risks of receptor agonists Alarming rise in weight loss

According to NICE Technology Appraisal 875, Wegovy is recommended only within a specialist weight management service for adults with a body mass index (BMI) of at least 35 kg/m and at least one weight-related comorbidity

Clinical studies have shown significant improvement in withdrawal symptoms in most patients treated with DSIP, with minimal side effects

They work through the growth hormone axis and are usually discussed for visceral fat, lean mass preservation, recovery, and body composition

By increasing the body's levels of GLP-1, Wegovy keeps food in the stomach for longer and sends signals to the brain that it's full helping regulate appetite and supporting significant weight loss